Estrella Immunopharma Inc. Cash Flow Conversion Efficiency
Estrella Immunopharma Inc. cash flow conversion efficiency. Based on the latest financial reports, Estrella Immunopharma Inc. (ESLA) has a cash flow conversion efficiency ratio of 0.240x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.78 Million) by net assets ($-7.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Estrella Immunopharma Inc. (2020–2025)
Cash flow conversion efficiency of Estrella Immunopharma Inc. from 2020 to 2025. This chart illustrates how Estrella Immunopharma Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Estrella Immunopharma Inc. (ESLA) stock price for real-time trading data and today's change.
Estrella Immunopharma Inc. Cash Flow Conversion Ratio Explained
Estrella Immunopharma Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Estrella Immunopharma Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Estrella Immunopharma Inc. ranked by their cash flow conversion efficiency. Also see Estrella Immunopharma Inc. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silvair Inc
WAR:SVRS
|
0.046x |
|
Southern Energy Corp
V:SOU
|
0.062x |
|
Dignitana AB
ST:DIGN
|
-0.115x |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
-0.184x |
|
Avalon Advanced Materials Ltd
TO:AVL
|
-0.011x |
|
Mohenz.Co.Ltd
KQ:006920
|
0.017x |
|
Fidelity Special Values
LSE:FSV
|
0.010x |
|
Drillcon AB
ST:DRIL
|
0.045x |
Annual Cash Flow Conversion Efficiency for Estrella Immunopharma Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Estrella Immunopharma Inc. from 2020 to 2025. Review Estrella Immunopharma Inc. financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-10.37 Million | $-1.79 Million | 0.172x | +100.80% |
| 2024-12-31 | $143.73K | $-3.11 Million | -21.662x | -476.12% |
| 2023-12-31 | $4.27 Million | $-16.07 Million | -3.760x | -2446.93% |
| 2022-12-31 | $7.07 Million | $-1.04 Million | -0.148x | -110.65% |
| 2021-12-31 | $-1.04 Million | $-1.44 Million | 1.387x | -- |
| 2020-12-31 | $0.00 | $-670.82K | x | -- |
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leuke… Read more